thought call
better growth linger legaci product concern
trend seen biotech report strong result
offer disappoint guidanc revenu adjust ep midpoint
think recent enthusiasm return growth
underappreci earn power thesi set stock poorli ahead notabl
style typic rais initi conserv guidanc throughout
year clearli jump revenu growth major
posit look five legaci franchis neupogen/neulasta epo aranesp
enbrel aggreg trend eros
maxim henc look otezla major addit
think even repatha aimovig biosimilar collect would add
off-set legaci franchis eros find
pipelin intrigu given de-risk phase data tezepelumab asthma
omecamtiv cardio registr phase data lung cancer
 impact skew time-frame recogn conservat
guidanc top end look much
upsid top-line otezla newer product base continu headwind
legaci product eros pipelin impact seem year away
keep neutral rate lower po
pipelin remain potenti bright spot compani futur busi
otezla track readout phase data mild-to-moder psoriasi mid-year
registr tezepelumab data expect phase data expect
first-in-human data expect posit data
program could warrant multipl expans versu near term impact
updat model forecast non-gaap ep
kept revenu forecast intact
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu nearli
neutral rate base peer growth
driven declin legaci product revenu
quit met grow new product launch
interest oncolog pipelin need de-risk
strong cash flow allow addit
share buyback dividend payment busi
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
million
po per share valu use sum part npv
analysi market pipelin drug assum rang
weight averag cost capit wacc approv drug
pipelin drug base stage approv product market life pipelin
develop termin growth rate new launch legaci
product po also reflect net cash
upsid risk price object slower expect eros neulasta
esa franchis faster growth aimovig repatha even prolia
better expect clinic trial result oncolog pipelin
downsid risk price object faster expect revenu eros
legaci brand slower expect growth new drug launch clinic trial
geoff meacham herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
compani
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
